Executives from Amazon, Walgreens, Blue Shield of California and PhRMA weighed in on how to fix the much-scrutinized pharmacy ...

Analyst Allen Lutz of Bank of America Securities reiterated a Sell rating on GoodRx Holdings (GDRX – Research Report), reducing the price ...

A PBM business model that focuses on either a capitation- or transaction-based prescription administration model with absolutely transparent disclosures of revenue streams coming to it from drug ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

they’ve changed their business model in ways that hurt American consumers and drive up prices for everyone. As the PBM market has become increasingly consolidated, with just three PBMs handling ...

The pharmacy benefit management (PBM) ecosystem is deeply broken. Not only does the current system lead to ultra-high pricing, particularly for specialty drugs, but it puts employees last, plain and ...

The lower price for members is due to a new Pharmacy Care Reimagined model that unbundles the traditional PBM model, company says. Susan Morse, Executive Editor Improving the Patient Financial ...

We continue to appreciate the narrow moat surrounding Cigna's business model in managed care ... and the late 2018 merger with top-tier pharmacy benefit manager Express Scripts (now called ...

Most employers have little idea what the pharmacy benefit managers they hire do with the money they exchange for the medications used by their employees, according to a KFF survey released ...

The company is working to address these issues through various initiatives, including the implementation of a new pharmacy reimbursement model called CostVantage. The PBM business, operated through ...

“This business model is a dead man walking,” Paul Markovich ... The payer replaced Caremark as its sole PBM last year, instead carving up pharmacy functions amid a handful of vendors.

insurer Blue Shield of California and drugmaker lobby PhRMA called for an end to the pharmacy benefit manager model during HLTH 2024, saying the middleman structure misaligns incentives and drives ...